Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global leader in recombinant technology, has launched the XPressMAX™ Cell-Free Protein Synthesis Kit (Cat#: CFKIT02), designed to accelerate AI-powered high-throughput screening pipelines for antibody drug discovery. The kit uses advanced cell-free protein synthesis technology to produce target proteins and antibodies in vitro, bypassing the limitations of traditional cell-based expression systems.
Based on an E. coli lysate fully supplemented with transcription and translation components, XPressMAX™ allows direct protein synthesis from plasmid or PCR templates. It supports rapid expression of VHH, scFv, Fab, and miniproteins, which are critical for antibody discovery. According to the company, the kit achieves synthesis in just three hours with a success rate greater than 99%, and it supports complex disulfide bonding for native folding and bioactivity without additional enhancers.
Dr. Rob Burgess, Chief Business Officer at Sino Biological US, Inc., stated, "Our XPressMAX™ is a significant advancement in research tools and reagents for next-generation therapeutic discovery. By combining rapid, reliable protein expression with intelligent screening, we are helping our partners compress antibody discovery timelines without compromising quality." Dr. Jie Zhang, General Manager, added, "AI is revolutionizing antibody screening, but it demands expression systems that can match its speed and throughput. XPressMAX™ achieves rapid, high-success expression of challenging proteins in as little as 3 hours."
Leveraging XPressMAX™, Sino Biological has established a high-throughput cell-free expression platform that validates over 2,000 scFv/VHH molecules in 3-4 weeks, matching AI's rapid iteration. This integration is crucial for drug discovery, where speed and accuracy are paramount. The kit's ability to produce proteins quickly and reliably directly addresses the bottleneck in validating AI-predicted antibody candidates.
The implications of this launch are significant for the biopharmaceutical industry. By reducing protein synthesis time from days or weeks to hours, XPressMAX™ enables researchers to iterate faster, potentially cutting development costs and time to market for new therapeutics. This is particularly important as AI continues to generate vast numbers of candidate molecules that require experimental validation.
Researchers can visit www.sinobiological.com to explore more about XPressMAX™ or request a free sample. The product page is available at https://www.sinobiological.com/other-products/cell-free-protein-synthesis-system-cfkit02, and additional details on cell-free solutions can be found at https://www.sinobiological.com/category/solutions/cell-free.
Sino Biological is an international reagent supplier and CRO service provider specializing in recombinant protein production and antibody development, serving researchers in over 90 countries. The launch of XPressMAX™ underscores the company's commitment to supporting next-generation therapeutic discovery with innovative tools.
